Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | PPARD | Q03181 | 6/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247197 | 0.97 | CES2 (0.44) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL11444101 | 0.97 | CES2 (0.40) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL27816034 | 0.92 | CES2 (0.44) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL1533838 | 0.92 | CES1 (0.39) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL10910268 | 0.87 | CES1 (0.36) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL7951570 | 0.86 | CES1 (0.39) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL6340629 | 0.81 | — | — | |
| SCHEMBL7879640 | 0.77 | CES2 (0.40) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL5048524 | 0.77 | CES2 (0.40) | CES2CES1LMNAMEN1KMT2A | |
| SCHEMBL506031 | 0.76 | CES2 (0.56) | CES2CES1MEN1KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| US-4739006-A | BLEND CONTAINING ACRYLIC ESTERS AND HYDROXY SUBSTITUTED ACRYLIC ESTERS | EXXON RESEARCH & ENGINEERING CO. (US) | 1988-04-19 | — | — | US | disclosed |
| US-4532294-A | Contacting mixture of hydroxyalkyl acrylate, other acrylates in presence of free radical initiator, liquid ester solvent | EXXON RESEARCH & ENGINEERING CO. (US) | 1985-07-30 | — | — | US | disclosed |
| US-4081279-A | Photothermographic materials containing radiation sensitive quinone compounds and nitrobenzylidene dyes | EASTMAN KODAK COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | CES2 4162/4885CES1 2162/4885LMNA 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.